Antibody Information
General Information of This Antibody
| Antibody ID | ANI0RYL003 |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Ciletatug |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRAQPGWGLEWMGLINPGSGGTNY
NEKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGYYGNSFAYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPLSLPVTPGEPASISCKSSQSLLNSGNQKNYLTWYLQKPGQSPQLLIYWASTR
ESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQNAYYYPYTFGGGTKVEIK Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
RC-118 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05205850 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open, multi-center phase 1/2a clinical study of RC118 for injection in patients with locally advanced unresectable or metastatic malignant solid tumors with positive expression of CLAUDIN 18.2.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04914117 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1, first-in-human, multicentre, open-label study of RC118 for injection in patients with locally advanced unresectable/metastatic solid tumours.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03895112 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 study of AVID200 in patients with myelofibrosis (myeloproliferative neoplasms research consortium [MPN-RC] 118).
|
||||
References